Literature DB >> 7911031

Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.

P Lipponen1, M Eskelinen.   

Abstract

The expression of epidermal growth factor receptor (EGFR) was studied immunohistochemically in 234 cases of transitional cell bladder cancer. EGFR was overexpressed in 35% of cases and distinct nuclear localisation of EGFR positivity was found in 31% of the tumours. Overexpression was related to invasive growth, grade 2-3 histology, non-papillary type, DNA aneuploidy and high proliferation rate of cancer cells. The expressions of p53 and EGFR were interrelated, while expression of c-erbB-2 was independent of EGFR expression. Progression of superficial tumours, recurrence-free survival and survival were independently related to overexpression of EGFR in multivariate analysis. T category, S-phase fraction and non-papillary type included all the available prognostic information when the entire cohort was analysed by multivariate methods. The results show that overexpression of EGFR is related to several malignant features and prognosis in superficial bladder cancer. Moreover, the results suggest that overexpression of EGFR is usually a late event in bladder cancer development related to genetic instability rather than an early event in malignant transformation. Further studies are still needed to establish whether the direct measurement of cell proliferation or analysis of growth factor receptors and other oncoproteins gives more accurate prognostic information in bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911031      PMCID: PMC1969432          DOI: 10.1038/bjc.1994.220

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  Chromatin binding of epidermal growth factor, nerve growth factor, and platelet-derived growth factor in cells bearing the appropriate surface receptors.

Authors:  E M Rakowicz-Szulczynska; U Rodeck; M Herlyn; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

2.  A computer program for comparing K samples with right-censored data.

Authors:  E T Lee; M M Desu
Journal:  Comput Programs Biomed       Date:  1972-11

Review 3.  Epidermal growth factor receptors.

Authors:  E D Adamson; A R Rees
Journal:  Mol Cell Biochem       Date:  1981-02-11       Impact factor: 3.396

Review 4.  The epidermal growth factor (EGF).

Authors:  S Cohen
Journal:  Cancer       Date:  1983-05-15       Impact factor: 6.860

5.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.

Authors:  T Yamamoto; S Ikawa; T Akiyama; K Semba; N Nomura; N Miyajima; T Saito; K Toyoshima
Journal:  Nature       Date:  1986 Jan 16-22       Impact factor: 49.962

6.  Monoclonal antibodies against the human epidermal growth factor receptor from A431 cells. Isolation, characterization, and use in the purification of active epidermal growth factor receptor.

Authors:  P J Parker; S Young; W J Gullick; E L Mayes; P Bennett; M D Waterfield
Journal:  J Biol Chem       Date:  1984-08-10       Impact factor: 5.157

7.  Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes.

Authors:  H Ushiro; S Cohen
Journal:  J Biol Chem       Date:  1980-09-25       Impact factor: 5.157

8.  Epidermal growth factor-like transforming growth factor. II. Interaction with epidermal growth factor receptors in human placenta membranes and A431 cells.

Authors:  J Massagué
Journal:  J Biol Chem       Date:  1983-11-25       Impact factor: 5.157

9.  The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor.

Authors:  A L Schechter; M C Hung; L Vaidyanathan; R A Weinberg; T L Yang-Feng; U Francke; A Ullrich; L Coussens
Journal:  Science       Date:  1985-09-06       Impact factor: 47.728

10.  In primary human breast carcinomas mutations in exons 5 and 6 of the p53 gene are associated with a high S-phase index.

Authors:  G R Merlo; A Bernardi; F Diella; T Venesio; A P Cappa; R Callahan; D S Liscia
Journal:  Int J Cancer       Date:  1993-06-19       Impact factor: 7.396

View more
  52 in total

Review 1.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

Review 2.  Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.

Authors:  David J McConkey; Woonyoung Choi; Lauren Marquis; Frances Martin; Michael B Williams; Jay Shah; Robert Svatek; Aditi Das; Liana Adam; Ashish Kamat; Arlene Siefker-Radtke; Colin Dinney
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

Review 3.  Growth factors in bladder cancer.

Authors:  M Liebert
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

Review 4.  Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function.

Authors:  Klaus Dittmann; Claus Mayer; H Peter Rodemann
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

5.  A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.

Authors:  Maha Hussain; Stephanie Daignault; Neeraj Agarwal; Petros D Grivas; Arlene O Siefker-Radtke; Igor Puzanov; Gary R MacVicar; Ellis Glenn Levine; Sandy Srinivas; Przemyslaw Twardowski; Mario A Eisenberger; David I Quinn; Ulka N Vaishampayan; Evan Y Yu; Scott Dawsey; Kathleen C Day; Mark L Day; Mahmoud Al-Hawary; David C Smith
Journal:  Cancer       Date:  2014-05-06       Impact factor: 6.860

6.  Biomarkers in bladder cancer: present status and perspectives.

Authors:  Wun-Jae Kim; Soongang Park; Yong-June Kim
Journal:  Biomark Insights       Date:  2007-03-27

Review 7.  Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.

Authors:  Margaret A Knowles; Fiona M Platt; Rebecca L Ross; Carolyn D Hurst
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

8.  Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.

Authors:  Peixin Dong; Zhujie Xu; Nan Jia; Dajin Li; Youji Feng
Journal:  Mol Cancer       Date:  2009-11-16       Impact factor: 27.401

9.  Conservative treatment of invasive bladder cancer.

Authors:  N J Rene; F B Cury; L Souhami
Journal:  Curr Oncol       Date:  2009-08       Impact factor: 3.677

10.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.